AstraZeneca reported positive phase III data for baxdrostat, an aldosterone synthase inhibitor acquired through its 2023 purchase of CinCor Pharma. The drug met primary and secondary endpoints by significantly reducing systolic blood pressure in patients with uncontrolled or resistant hypertension. Baxdrostat demonstrated a favorable safety profile and outperformed a placebo across multiple subgroups, reinforcing its potential as a novel treatment mechanism in a space with limited recent innovation. These results support AstraZeneca’s $1.3 billion investment in CinCor and position baxdrostat for regulatory filings.